ArticleInternational journal of molecular sciences2022

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.

Katja Seipel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.